SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
---------------------------
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED):
August 6, 2002
---------------------------
V. I. TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-24241 11-3238476
(State or other jurisdiction of (Commission File Number) (IRS employer
incorporation or organization) identification No.)
134 Coolidge Avenue
Watertown, Massachusetts 02472
(617) 926-1551
(Address, including zip code, and telephone number, including area
code, of registrant's principal executive offices)
ITEM 5. OTHER EVENTS
On August 6, 2002, V. I. Technologies, Inc. ("Vitex") modified its
partnership with Pall Corporation for the INACTINE(TM) red blood cell pathogen
inactivation system. A copy of the joint Vitex and Pall Corporation press
release dated August 7, 2002 is attached as Exhibit 99.1 to this current report
on Form 8-K.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits:
99.1 Joint Press Release of V. I. Technologies, Inc. and
Pall Corporation dated August 7, 2002.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
V. I. TECHNOLOGIES, INC.
Dated: August 8, 2002 By: /s/ John R. Barr
---------------------------------
John R. Barr, President and Chief
Executive Officer
EXHIBIT INDEX
Exhibit
No. Description
------- -----------
99.1 Joint Press Release of V.I. Technologies, Inc. and
Pall Corporation dated August 7, 2002.